Viyash Scientific

Viyash Scientific OCF Margin

The Operating Cash Flow Margin of Viyash Scientific (VIYASH.NS) as of Nov 4, 2026 is 5.37 %. In the previous year, Operating Cash Flow Margin was 2.23 % — a change of 140.57% (higher).

OCF Margin

5.37 %

YoY

140.57%

Last updated:

Operating Cash Flow Margin of Viyash Scientific is 2025 5.37 % . Operating Cash Flow Margin of Viyash Scientific was 2024 2.23 % . It decreases by 140.57% higher compared to the previous year.

The Viyash Scientific OCF Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

OCF Margin
Date
OCF Margin
Jan 1, 2018
5.33 INR
Jan 1, 2019
11.16 INR
Jan 1, 2020
9.78 INR
Jan 1, 2021
8.43 INR
Jan 1, 2022
2.27 INR
Jan 1, 2023
1.18 INR
Jan 1, 2024
2.23 INR
Jan 1, 2025
5.37 INR
The Viyash Scientific OCF Margin history
YEAROCF MarginYoY
5.37 %+140.57%
2.23 %+88.83%
1.18 %-47.87%
2.27 %-73.07%
8.43 %-13.83%
9.78 %-12.39%
11.16 %+109.60%
5.33 %-610.39%
-1.04 %+12,869.13%
-0.01 %-99.85%
-5.31 %-53.02%
-11.31 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Viyash Scientific Stock analysis

What does Viyash Scientific do? Viyash Scientific Ltd generates revenue through the manufacturing and sale of veterinary pharmaceuticals and specialty chemicals. The company offers finished dose formulations, active pharmaceutical ingredients (APIs), and analytical services to clients in the pharmaceutical, personal care, and nutraceutical industries. Its products target therapies such as anthelmintics, anti-protozoals, nutraceuticals, NSAIDs, anti-infectives, and dermatology solutions. The firm operates primarily through its pharmaceuticals segment, with subsidiaries Alivira Animal Health Limited and SeQuent Research Limited supporting its analytical and bioanalytical service offerings. The company's analytical services include method validation, stability testing, microbiology, and in-house method development, adhering to pharmacopoeia monographs and customer-specific requirements. These services are provided to API, pharmaceutical, personal care, and nutraceutical companies seeking regulatory compliance and quality assurance. The firm's focus on targeted therapies and specialized services positions it to serve a niche market within the animal health sector. Viyash Scientific Ltd's revenue streams are derived from both product sales and service contracts. The pharmaceuticals segment, which includes APIs and finished formulations, represents a core business area, while analytical services form a complementary revenue source. The company leverages its subsidiaries to enhance its service capabilities, particularly in analytical and bioanalytical support for clients across multiple industries. Viyash Scientific is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Viyash Scientific stock

Operating Cash Flow Margin of Viyash Scientific is 5.37 % in 2025.

Operating Cash Flow Margin of Viyash Scientific changed from 2.23 % to 5.37 %, representing a 140.57% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Operating Cash Flow Margin Viyash Scientific since 2006 – with annual values, charts, and detailed analysis.

OCF margin measures the percentage of revenue converted into operating cash flow. It indicates cash generation efficiency from core business operations.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Operating Cash Flow Margin's Viyash Scientific with sector peers and the industry average to assess whether it is attractive.

To evaluate Operating Cash Flow Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Operating Cash Flow Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Viyash Scientific

All Key Metrics — Viyash Scientific